Reinforcing the mucus: A new therapeutic approach for ulcerative colitis?

Gut

Volumn 54, Issue 7, 2005, Pages 900-903

  Gibson, P R ^a,b   Muir, J G ^a  

^a MONASH UNIVERSITY   (Australia)

^b BOX HILL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

ANTIINFLAMMATORY ACTIVITY; COLON MUCOSA; HUMAN; HYDROPHOBICITY; MUCOSA INFLAMMATION; MUCUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; HUMANS; MUCUS; PHOSPHOLIPIDS;

EID: 21044446805     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.058453     Document Type: Review

References (44)

1. Gibson PR. Ulcerative colitis-an epithelial disease? Ballieres Clin Gastroenterol 1997;1:17-33.
2. Pallone F, Monteleone G, Monteleane I, et al. The immune system in inflammatory bowel disease. In: Satsangi L, Sutherland LR, eds. inflammatory bowel diseases. Edinburgh: Churchill Livingstone, 2003:85-93.
3. Pavli P, Gibson PR. Pathogenic factors in inflammatory bowel disease. II. Crohn's disease. Dig Dis 1992;10:72-86.
4. Roediger WEW. The colonic epithelium in ulcerative colitis-an energy deficiency disease? Lancet 1980;2:712-15.
5. Ramakrishna BS, Roberts-Thompson JC, Pannall PR, et al. Impaired sulpnation of phenol by the colonic mucosa in quiescent and active ulcerative colitis. Gut 1991;32:46-9.
6. Gibson PR, Rosella O. Interleukin-8 secretion by colonic crypt cells in vitro: a response to injury that is suppressed by butyrate and enhanced in inflammatory bowel disease. Gut 1995;37:536-43.
7. Gibson PR, Rosella O. Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis. Inflamm Bowel Dis 1996;2:105-14.
8. Gibson P, Rosella R, Nov R, et al. Colonic epithelium is diffusely abnormal in ulcerative colitis and colorectal carcinoma. Gut 1995;36:857-63.
9. Pullan RD, Thomas GA, Rhodes M, et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994;35:353-9.
10. Rhodes JM, Black RR, Gallimore R, et al. Histochemical demonstration of desialation and desulphation of normal and inflammatory bowel disease rectal mucus by faecal extracts. Gut 1985;26:1312-18.
11. Raouf AH, Tsai HH, Parker N, et al. Sulphation of colonic and rectal mucin in inflammatory bowel disease: reduced sulphation of rectal mucus in ulcerative colitis. Clin Sci 1992;83:623-6.
12. Morita H, Kettlewell MG, Jewell DP, et al. Glycosylation and sulphation of colonic mucus glycoproteins in patients with ulcerative colitis and in healthy subjects. Gut 1993;34:926-32.
13. Ehehalt R, Wagenblast J, Erben G, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray tandem mass spectrometry. Scand J Gastroenterol 2004;39:737-42.
14. Howarth GS, Xian a, Read LC. Insulin-like growth factor-1 partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol 1998;33:180-90.
15. FitzGerald AJ, Pu M, Marchbank T, et al. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides 2004;25:793-801.
16. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996;41:2254-9.
17. Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004;127:502-13.
18. Tsai HH, Dwarakanath AD, Hart CA, et al. Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment. Gut 1995;36:570-6.
19. Hills BA. Surface-acting phospholipid: a Pandora's box of clinical applications. Part II. Barrier and lubricating properties. Int Med J 2002;32:242-51.
20. Lichtenberger LM. The Hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-83.
21. Clamp J. The role of mucus in human intestinal defence. In: Losowsky MS, Heatley RV, eds. Gut defences in clinical practice. Edinburgh: Churchill Livingstone, 1986:83-94.
22. Lake AM, Bloch KJ, Neutra MR, et al. Intestinal goblet cell mucus release. II. In vivo stimulation by antigen in the immunized rat. J Immunol 1979;122:834-7.
23. Brandtzaeg P. Molecular and cellular aspects of the secretory immunoglobulin system. APMIS 1995;103:1-19.
24. Weinberg, ed. Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol 2001;53:1303-10.
25. Sands BE, Podolsky DK. The trefoil peptide family. Annu Rev Physiol 1996;58:253-73.
26. Prokazova NV, Zvezdina ND, Korotaeva AA. Effect of lysophosphatidylcholine on transmembrane signal transduction. Biochemistry 1998;63:31-7.
27. Hills BA. Surface-acting phospholipid: a Pandora's box of clinical applications. Part I. The lung and air spaces. Int Med J 2002;32:170-8.
28. Wright MM, Howe AG, Zaremberg V. Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem Cell Biol 2004;82:18-28.
29. Iwamoto M, Koji T, Makiyama K, et al. Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol 1996;180:152-9.
30. Kruidenier L, Kuiper I, Lamers CB, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol 2003;201:28-36.
31. Minami T, Tojo H, Shinomura Y, et al. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 1994;35:1593-9.
32. Morito H, Nakanishi K, Dohi T, et al. Phospholipid turnover in the inflamed intestinal mucosa: arachidonic acid-rich phosphatidyl/ plasmenyl-ethanolamine in the mucosa in inflammatory bowel disease. J Gastroenterol 1999;34:46-53.
33. Minami T, Shinomura Y, Miyagawa J, et al. Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease. Am J Gastroenterol 1997;92:289-92.
34. Brown JF, Chang Q, Soper BD, et al. Protein kinase C mediates experimental colitis in the rat. Am J Pnysiol 1999;276:G583-90.
35. Nishizulca Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-14.
36. Sakanoue Y, Hatada T, Horai T, et al. Protein kinase C activity of colonic mucosa in ulcerative colitis. Scand J Gastroenterol 1992;27:275-80.
37. Glatz JA, Muir JG, Murray AW. Direct evidence for phorbol ester-stimulated accumulation of diacylglycerol derived from phosphatidylcholine. Carcinogenesis 1987;8:1943-5.
38. Schultsz C, Van Den Berg FM, Ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999;117:1089-97.
39. Kleessen B, Kroesen AJ, Buhr HJ, et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002;37:1034-41.
40. Gjone E. Plasma phospholipids in ulcerative colitis. A quantitative thin layer Chromatographic study. Scand J Clin Lab Invest 1966;18:263-7.
41. Fabia R, Ar'Rajab A, Willen R, et al. Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat. Digestion 1992;53:35-44.
42. Mourelle M, Guarner F, Malagelada JR. Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology 1996;110:1093-7.
43. Stremmel W, Merle U, Zahn A, et al. Retarded release phsophatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-71.
44. Mariadason JM, Catto-Smith A, Gibson PR. Modulation of distal colonic epithelial barrier function by dietary fibre in normal rats. Gut 1999;44:394-9.